Boljevic Darko, Bojic Milovan, Farkic Mihajlo, Sagic Dragan, Topic Dragan, Kovacevic Vladimir, Lakcevic Jovana, Veljkovic Stefan, Dobric Milan, Hinic Sasa, Ilijevski Nenad, Nikolic Marko, Kaludjerovic Aleksandra, Bunc Matjaz, Nikolic Aleksandra
Dedinje Cardiovascular Institute, Belgrade, Serbia.
School of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.
Front Cardiovasc Med. 2022 May 24;9:882854. doi: 10.3389/fcvm.2022.882854. eCollection 2022.
Severe aortic stenosis, a highly-common valve disease in the elderly, has a poor prognosis if left untreated. To address the concern of effective procedures for severe aortic stenosis, a systematic TAVI program was established at the Dedinje Cardiovascular Institute (Belgrade, Serbia).
Our cohort was composed of 56 patients (74±15 years old). The mean logistic EuroScore was 10.17%; the mean Society of Thoracic Surgeons score was 3.22%. One third of the patients were categorized as class III or IV of the New York Heart Association (NYHA). The valves selected for use were either self-expandable or balloon expandable (Evolut R, Medtronic; Acurate Neo, Boston Scientific and Myval, Meril). The choice of valve type was made by the Institute's Structural Heart Team, in accordance with the patient's native aortic valve, size and calcification of ilio-femoral vessels, as well as the need for alternative access. TAVI procedure was conducted according to current guidelines provided by the European Society of Cardiology.
The procedure success rate was 100%. Trans-femoral approach was achieved in 100% of patients; percutaneously in 87.5%, while a surgical cut was necessary in 12.5%. No patient showed moderate or severe aortic regurgitation after the procedure, although trace or mild regurgitation was recorded in 30.3%. Permanent pacemaker was implanted in one patient (1.78%), contrast induced acute kidney injury occured in one patient (1.78%), no stroke was recorded, and three pseudo-aneurysms which required surgical intervention occurred. Three patients required blood transfusions (5.33%). A 30-day all-cause mortality rate was 1.78%.
The Dedinje Cardiovascular Institute spearheaded all efforts to establish a TAVI program in Serbia. Our initial TAVI results are promising, encouraging, and comparable with the results of previous large randomized trials. This initial experience opens the door for further development with a goal of our Institute to become a high-volume TAVI center.
重度主动脉瓣狭窄是老年人中一种非常常见的瓣膜疾病,如果不进行治疗,预后较差。为了解决重度主动脉瓣狭窄有效治疗方法的问题,塞尔维亚贝尔格莱德的德丁耶心血管研究所建立了一个系统性经导管主动脉瓣置换(TAVI)项目。
我们的队列由56名患者组成(年龄74±15岁)。平均逻辑欧洲心脏手术风险评估系统(EuroScore)为10.17%;平均胸外科医师协会(STS)评分为3.22%。三分之一的患者被归类为纽约心脏协会(NYHA)III级或IV级。所选用的瓣膜为自膨胀式或球囊膨胀式(美敦力公司的Evolut R、波士顿科学公司的Acurate Neo以及梅里尔公司的Myval)。瓣膜类型的选择由该研究所的结构性心脏病团队根据患者的原生主动脉瓣、髂股血管的尺寸和钙化情况以及替代入路的需求来决定。TAVI手术按照欧洲心脏病学会提供的现行指南进行。
手术成功率为100%。100%的患者采用经股动脉入路;其中87.5%为经皮穿刺,12.5%需要进行手术切口。术后没有患者出现中度或重度主动脉瓣反流,不过有30.3%的患者记录到微量或轻度反流。1名患者(1.78%)植入了永久性起搏器,1名患者(1.78%)发生了造影剂诱导的急性肾损伤,未记录到中风病例,出现了3例假性动脉瘤,需要进行手术干预。3名患者需要输血(5.33%)。30天全因死亡率为1.78%。
德丁耶心血管研究所在塞尔维亚率先开展了建立TAVI项目的各项工作。我们TAVI的初步结果令人鼓舞,与之前大型随机试验的结果相当。这一初步经验为进一步发展打开了大门,我们研究所的目标是成为一个高容量TAVI中心。